Want to see SDZNY full AI Analyst Report?
SDZNY Stock Chart & Stats
$75.80
$0.55(1.34%)
At close: 4:00 PM EST
$75.80
$0.55(1.34%)
Day’s Range― - ―
52-Week Range$52.53 - $93.65
Previous CloseN/A
Volume11.52K
Average Volume (3M)17.90K
Market Cap
$39.56B
Enterprise Value$41.20B
Total Cash (Recent Filing)$1.74B
Total Debt (Recent Filing)$5.68B
Price to Earnings (P/E)42.0
Beta0.63
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.98%
Share Statistics
EPS (TTM)2.12
Shares Outstanding440,000,000
10 Day Avg. Volume5,853
30 Day Avg. Volume17,903
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.34
Price to Sales (P/S)2.81
P/FCF Ratio38.74
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue3.71
Enterprise Value/Gross Profit7.86
Enterprise Value/Ebitda18.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biosimilars Mix ExpansionA sustained shift toward higher-value biosimilars (≈30% of sales) materially improves revenue quality versus commoditized generics. Over 2–6 months this mix supports higher margins, stronger pricing power in tenders/formulary negotiations, and a larger addressable market as launches progress.
Margin Expansion And Stable Gross MarginsMeaningful margin expansion (160bps to 21.7%) and a ~50% gross margin reflect durable operating leverage from mix improvement and cost discipline. If sustained, higher core margins provide recurring cash to fund R&D, CapEx for biosimilars, and resilience against ongoing price pressure.
Improved Cash Flow And Manageable LeverageStronger free cash flow and reduced leverage (net debt/EBITDA ~1.5x; improving equity) enhance financial flexibility to fund peak biosimilars CapEx, acquisitions, and working capital. This balance-sheet capacity lowers refinancing risk and supports long-term strategic investments.
Bears Say
Persistent Price ErosionSustained low- to mid-single-digit price erosion is structural in generics and compresses top-line growth and unit economics. Over months this reduces revenue per unit, forces ongoing productivity or mix improvements to protect margins, and makes forecasting organic growth more uncertain.
Regulatory And IP UnpredictabilityUncertain patent/IP and regulatory outcomes in the U.S. can delay or block biosimilar market entry, shifting expected revenue timing and eroding first-mover advantages. Over 2–6 months, this risk can materially alter uptake curves and the business case for individual launches.
High Near-term CapEx And One-off Integration CostsSubstantial peak CapEx for biosimilars and material one-off integration/IT expenses increase cash demands and extend payback periods. Even with improving cash flow, elevated investment and non-capex costs pressure free cash conversion and constrain cash available for other strategic uses in the near term.
Sandoz Group Ltd Sponsored ADR News
SDZNY FAQ
What was Sandoz Group Ltd Sponsored ADR’s price range in the past 12 months?
Sandoz Group Ltd Sponsored ADR lowest stock price was $52.53 and its highest was $93.64 in the past 12 months.
What is Sandoz Group Ltd Sponsored ADR’s market cap?
Sandoz Group Ltd Sponsored ADR’s market cap is $39.56B.
When is Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date?
Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date is Aug 05, 2026 which is in 30 days.
How were Sandoz Group Ltd Sponsored ADR’s earnings last quarter?
Sandoz Group Ltd Sponsored ADR released its earnings results on Feb 25, 2026. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of N/A by $1.24.
Is Sandoz Group Ltd Sponsored ADR overvalued?
According to Wall Street analysts Sandoz Group Ltd Sponsored ADR’s price is currently Overvalued.
Does Sandoz Group Ltd Sponsored ADR pay dividends?
Sandoz Group Ltd Sponsored ADR pays a Annually dividend of $1.021 which represents an annual dividend yield of 0.98%. See more information on Sandoz Group Ltd Sponsored ADR dividends here
What is Sandoz Group Ltd Sponsored ADR’s EPS estimate?
Sandoz Group Ltd Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sandoz Group Ltd Sponsored ADR have?
Sandoz Group Ltd Sponsored ADR has 440,000,000 shares outstanding.
What happened to Sandoz Group Ltd Sponsored ADR’s price movement after its last earnings report?
Sandoz Group Ltd Sponsored ADR reported an EPS of $1.24 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 10.537%.
Which hedge fund is a major shareholder of Sandoz Group Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in SDZNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sandoz Group Ltd Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
SDZNY Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 55.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.22%
12-Months-Change
Fundamentals
Return on Equity
10.09%
Trailing 12-Months
Asset Growth
10.67%
Trailing 12-Months
Company Description
Sandoz Group Ltd Sponsored ADR
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
SDZNY Company Deck
SDZNY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strongly positive operational and financial performance with multiple clear achievements: revenue exceeded $11 billion, biosimilars gained share and drove margin expansion, cash generation and EPS improved materially, and strategic investments (Just-Evotec acquisition and a Slovenian biosimilars hub) position the company for future growth. Notable near-term headwinds include penicillin B2B price disruption, ongoing low- to mid-single-digit price erosion, FX impacts on reported net debt, one-off integration and IT costs, and regulatory/IP uncertainties (especially in the U.S.) that could affect timing and scale of some opportunities. On balance, the highlights (broad-based sales growth, margin expansion, strong cash flow, successful launches, strengthened pipeline and manufacturing investments) outweigh the lowlights, which are significant but largely manageable and either transient or being mitigated through strategic actions.View all SDZNY earnings summariesTechnical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Ownership Overview
―
Insiders
0.19% Mutual Funds
<0.01% Other Institutional Investors
99.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---